Multimarker versus biochemical first-trimester risk assessment for fetal chromosomal anomalies: a retrospective cohort study
Open Access
- 25 October 2026
- journal article
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 9 (6) , 1565-1573
Abstract
Aims: To compare the diagnostic performance of biochemical risk assessment alone with that of a multimarker first-trimester risk assessment combining biochemical and sonographic parameters for screening of fetal chromosomal anomalies. Methods: This retrospective observational study included singleton pregnancies evaluated at a tertiary perinatology clinic between January 2022 and January 2026. Pregnancies undergoing first-trimester screening at 11+0 to 13+6 weeks of gestation were included. Biochemical risk was calculated using maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A, whereas multimarker risk was derived from maternal characteristics, biochemical markers, and sonographic findings, including nuchal translucency and selected additional markers when available. The primary outcome was confirmed fetal chromosomal anomaly. Diagnostic indices and receiver operating characteristic (ROC) analyses were performed. Results: A total of 1,248 singleton pregnancies were analyzed, including 42 fetuses (3.4%) with chromosomal anomalies. Compared with the biochemical model, the multimarker model showed higher sensitivity (81.0% vs 69.0%), specificity (95.7% vs 92.6%), positive predictive value (39.5% vs 24.6%), and overall accuracy (95.2% vs 91.8%). The false-positive rate was lower with the multimarker approach (4.3% vs 7.4%). ROC analysis demonstrated superior discriminative performance for the multimarker model (AUC: 0.903 vs 0.812, p<0.001). Conclusion: Multimarker first-trimester risk assessment provided better overall diagnostic performance than biochemical risk assessment alone, particularly in terms of specificity, accuracy, and reduction of false-positive results. These estimates should be interpreted in light of the retrospective design, partial verification bias, and the limited number of affected pregnancies.Keywords
Funding Information
- The authors declare that this study received no financial support.
This publication has 21 references indexed in Scilit:
- Society for Maternal‐Fetal Medicine Consult Series #74: Cell‐free DNA screening for aneuploidies: Updated guidancePregnancy, 2025
- ISUOG Practice Guidelines (updated): performance of 11–14‐week ultrasound scanUltrasound in Obstetrics & Gynecology, 2023
- First‐trimester risk assessment based on ultrasound and cell‐free DNA vs combined screening: a randomized controlled trialUltrasound in Obstetrics & Gynecology, 2018
- Analysis of cell‐free DNA in maternal blood in screening for aneuploidies: updated meta‐analysisUltrasound in Obstetrics & Gynecology, 2017
- ISUOG updated consensus statement on the impact of cfDNA aneuploidy testing on screening policies and prenatal ultrasound practiceUltrasound in Obstetrics & Gynecology, 2017
- First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screeningCochrane Database of Systematic Reviews, 2017
- Clinical implementation of routine screening for fetal trisomies in the UKNHS: cell‐free DNA test contingent on results from first‐trimester combined testUltrasound in Obstetrics & Gynecology, 2015
- First‐trimester screening for chromosomal abnormalities by integrated application of nuchal translucency, nasal bone, tricuspid regurgitation and ductus venosus flow combined with maternal serum free β‐hCG and PAPP‐A: a 5‐year prospective studyUltrasound in Obstetrics & Gynecology, 2011
- First‐trimester screening for trisomy 21 by free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A: impact of maternal and pregnancy characteristicsUltrasound in Obstetrics & Gynecology, 2008
- Multicenter study of first‐trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk‐orientated two‐stage first‐trimester screeningUltrasound in Obstetrics & Gynecology, 2005